Problem

Pyrls addresses the clinical-workflow problem of finding reliable, comprehensive medication information quickly. Pharmacists and other clinicians often have to search multiple sources or toggle between systems, disrupting care delivery; the partnership announcement frames this as a critical workflow challenge. The main use case is point-of-care support while prescribing, dispensing, selecting drugs, counseling patients, or checking interactions. The economic pain is primarily clinician time and workflow friction, with additional safety and care-quality consequences, although the available evidence does not quantify the cost in dollars.

Product / Service

Pyrls is a digitally native drug-information platform delivered through a website, mobile applications, and a browser extension. It combines concise drug monographs with clinician-curated, guideline-driven pharmacotherapy content, including more than 800 general drug summaries and 50-plus pharmacotherapy charts. Its free tier covers core drug information, knowledge checks, calculators, and web/mobile access, while the Pro tier adds counseling points, clinical reviews, dosing and adjustments, interaction checking, pharmacotherapy reviews, and expanded tables and charts.

The delivery model is freemium for individuals, with Pro priced at $15 per month when paid annually or $40 per month when paid monthly, plus organization offerings with analytics, custom content, and single sign-on. Pyrls can also be embedded into clinical workflow software, as shown by its integration with EQUIPP Copilot, putting summaries, counseling points, pill identification, and interaction screening where pharmacists already work. The benefit is faster access to practical information without leaving the workflow, supporting more efficient decisions and patient conversations.

Market

Pyrls competes in digital drug information and clinical decision-support software for pharmacists, physicians, nurses, advanced-practice clinicians, students, and healthcare organizations. Its adjacent or direct reference competitors include PDR, which offers searchable drug information, interaction detection, and pill identification, and Wolters Kluwer’s UpToDate Lexidrug/Facts and Comparisons, which provides pharmacist-focused evidence, drug comparisons, interactions, dosing, and extensive drug tables. Pyrls’s positioning is more digitally native and workflow-oriented, emphasizing concise summaries, clinician-curated insights, and modern web and mobile access; the evidence does not provide a formal company-published competitor list.

Pyrls is not pre-revenue. A January 2025 profile reported more than 10,000 paying subscribers, 50,000 free users, and revenue that had doubled over the prior year. Y Combinator lists the company as an active Winter 2022 SaaS company and reported 50,000-plus clinicians and trainees and hundreds of organizations, while a December 2025 partnership announcement reported that more than 100,000 clinicians relied on Pyrls. These figures use different dates and user definitions, but together indicate meaningful adoption and paid demand rather than a pre-revenue product; the available evidence does not include audited financials.